Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activities
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Asset Writedowns and Impairment (2023)

Acro Biomedical has reported Asset Writedowns and Impairment over the past 1 years, most recently at $480000.0 for Q3 2023.

  • Quarterly results put Asset Writedowns and Impairment at $480000.0 for Q3 2023, changed N/A from a year ago — trailing twelve months through Dec 2024 was $480000.0 (changed N/A YoY), and the annual figure for FY2023 was $480000.0, changed.
  • Asset Writedowns and Impairment for Q3 2023 was $480000.0 at Acro Biomedical.
  • Over the last five years, Asset Writedowns and Impairment for ACBM hit a ceiling of $480000.0 in Q3 2023 and a floor of $480000.0 in Q3 2023.